PMID- 9314567
OWN - NLM
STAT- MEDLINE
DCOM- 19971113
LR  - 20240213
IS  - 0022-1007 (Print)
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Linking)
VI  - 186
IP  - 7
DP  - 1997 Oct 6
TI  - Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA 
      induce antitumor immunity against central nervous system tumors.
PG  - 1177-82
AB  - Recent studies have shown that the brain is not a barrier to successful active 
      immunotherapy that uses gene-modified autologous tumor cell vaccines. In this 
      study, we compared the efficacy of two types of vaccines for the treatment of 
      tumors within the central nervous system (CNS): dendritic cell (DC)-based 
      vaccines pulsed with either tumor extract or tumor RNA, and cytokine 
      gene-modified tumor vaccines. Using the B16/F10 murine melanoma (B16) as a model 
      for CNS tumor, we show that vaccination with bone marrow-generated DCs, pulsed 
      with either B16 cell extract or B16 total RNA, can induce specific cytotoxic T 
      lymphocytes against B16 tumor cells. Both types of DC vaccines were able to 
      protect animals from tumors located in the CNS. DC-based vaccines also led to 
      prolonged survival in mice with tumors placed before the initiation of vaccine 
      therapy. The DC-based vaccines were at least as effective, if not more so, as 
      vaccines containing B16 tumor cells in which the granulocytic macrophage 
      colony-stimulating factor gene had been modified. These data support the use of 
      DC-based vaccines for the treatment of patients with CNS tumors.
FAU - Ashley, D M
AU  - Ashley DM
AD  - Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 
      27710, USA.
FAU - Faiola, B
AU  - Faiola B
FAU - Nair, S
AU  - Nair S
FAU - Hale, L P
AU  - Hale LP
FAU - Bigner, D D
AU  - Bigner DD
FAU - Gilboa, E
AU  - Gilboa E
LA  - eng
GR  - NS20023/NS/NINDS NIH HHS/United States
GR  - P50 NS020023/NS/NINDS NIH HHS/United States
GR  - CA11898/CA/NCI NIH HHS/United States
GR  - CA61227/CA/NCI NIH HHS/United States
GR  - R37 CA011898/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cell Extracts)
RN  - 0 (RNA, Neoplasm)
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells
MH  - *Cancer Vaccines/immunology
MH  - Cell Extracts/immunology
MH  - Central Nervous System Neoplasms/genetics/immunology/pathology/*therapy
MH  - Dendritic Cells/*immunology
MH  - Histocytochemistry
MH  - Immunotherapy
MH  - Melanoma, Experimental/genetics/immunology/pathology/*therapy
MH  - Mice
MH  - RNA, Neoplasm/*immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Tumor Cells, Cultured
PMC - PMC2199074
EDAT- 1997/10/07 00:00
MHDA- 1997/10/07 00:01
PMCR- 1998/04/06
CRDT- 1997/10/07 00:00
PHST- 1997/10/07 00:00 [pubmed]
PHST- 1997/10/07 00:01 [medline]
PHST- 1997/10/07 00:00 [entrez]
PHST- 1998/04/06 00:00 [pmc-release]
AID - 10.1084/jem.186.7.1177 [doi]
PST - ppublish
SO  - J Exp Med. 1997 Oct 6;186(7):1177-82. doi: 10.1084/jem.186.7.1177.